The FDA advised medical professionals to stop prescribing asthma drugs with both long-acting beta agonists and inhaled corticosteroids because there is a risk of aggravating symptoms. LABAs should always be administered through a combination product and taken for the shortest possible time by patients who do not respond to other asthma treatments, according to the FDA's guidance.

Related Summaries